Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Biogen CEO Gets 7 percent 2008 Compensation Boost

By Pharmaceutical Processing | April 2, 2009

NEW YORK (AP) — Biogen Idec Inc.’s President and Chief Executive James C. Mullen received a 7 percent boost in total compensation in 2008, mainly due to a larger performance-based bonus, according to an Associated Press analysis to data filed with regulators Wednesday. Overall, his compensation totaled just over $11.3 million, including a salary bump of 4 percent to nearly $1.2 million and a performance-based cash bonus of $2.4 million, up about 24 percent year-over-year. Above-market earnings on deferred compensation totaled $96,352, and perks rose 61 percent to $257,919, including retirement contributions and tax planning reimbursements. The bulk of Mullen’s compensation came in the form of restricted stock and options with an estimated value of just under $7.4 million when they were granted on Feb. 13, 2008, according to a Securities and Exchange Commission filing on Wednesday. However, the options are “underwater,” since their $63.24-per-share exercise price is above Biogen’s current stock price of $51.88. That means the options are of little value absent a rebound in shares. The Associated Press formula is designed to isolate the value the company’s board placed on the executive’s total compensation package during the last fiscal year. It includes salary, bonus, performance-related bonuses, perks, above-market returns on deferred compensation and the estimated value of stock options and awards granted during the year. The calculations don’t include changes in the present value of pension benefits, and they sometimes differ from the totals companies list in the summary compensation table of proxy statements filed with the Securities and Exchange Commission, which reflect the size of the accounting charge taken for the executive’s compensation in the previous fiscal year. Mullen, 50, guided Cambridge, Mass.-based Biogen through a tumultuous year of increased scrutiny from Wall Street over lackluster sales of the multiple sclerosis drug Tysabri. In 2008, Biogen and partner Elan Corp. reported four cases of a rare brain infection in patients taking the drug. Concerns about the disease, called progressive multifocal leukoencephalopathy, caused Tysabri to be pulled from the market in 2005. Sales resumed the following year, with restrictions. Though the company successfully staved off a takeover attempt by activist investor Carl Icahn in June, he has since come back for another round. Previously, he accused the company of rigging its search for a buyout partner so it would fail. The company has denied that allegation. In its proxy filing Wednesday, Biogen said it recommends shareholders elect each of its board’s nominees and not the slate to be proposed by Icahn when the company’s annual meeting takes place on a date yet to be determined. The company also is proposing to amend its bylaws to require that directors be elected by majority vote. If a director up for reelection failed to meet that mark, the company wants to be able to require that person to resign. In 2008, Biogen’s profit rose 23 percent to $783.2 million while revenue rose 29 percent to $4.1 billion. Shares, though, fell 16 percent to end the year at $47.63.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE